Prior Agreement Sample Contracts

Share Cite Term
Link

Embed (HTML)
root9B Technologies Inc. – April 14, 2016 Miriam Blech 1271 Avenue of the Americas, 16th Floor New York, NY 10020 River Charitable Remainder Unitrust F/B/O Isaac Blech 1271 Avenue of the Americas, 16th Floor New York, NY 10020 Re: Amendment to Prior Agreements Ladies and Gentlemen: (April 20th, 2016)

As you know, root9B Technologies, Inc., a Delaware corporation (the "Company"), and each of Miriam Blech and River Charitable Remainder Unitrust f/b/o Isaac Blech (the "Investors") have entered into a series of agreements which include: (i) an Exchange Agreement dated August 11, 2015 (the "Exchange Agreement") whereby, among other things, the Company agreed to issue the Investors new warrants (the "Replacement Warrants") with the condition that such warrants would not be exercised, and the shares of common stock underlying such warrants need not be reserved by the Company until such time as the Company's stockholders agreed to increase the authorized capital stock of the Company, (ii) a letter agreement dated February 9, 2016 whereby, among other things, the Investors agreed to postpone certain dividends (the "Dividends") relating to their Series C Preferred stock issued by the Company until such time as the Company's stockholders agreed to increase the authorized capital stock of the

Identive Group – 39300 Civic Center Dr., Suite 140 Fremont, CA 94538 (September 16th, 2015)

Identiv, Inc. (the Company) is pleased to offer you continued employment in the position of President, effective as of September 9, 2015 (the Effective Date). You shall report to the Companys Chief Executive Officer. You agree that, during your service at the Company, you shall not engage in any other employment, consulting or other business activity without the prior written consent of the Company.

Seres Therapeutics, Inc. – Amended and Restated Investors Rights Agreement (May 27th, 2015)

THIS AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT is made as of the 19th day of December, 2014, by and among Seres Health, Inc., a Delaware corporation (the Company), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an Investor.

EXCO Resources, Inc. – Exco Resources, Inc. Amended and Restated Retention Agreement (May 20th, 2015)

This Amended and Restated Retention Agreement (this Agreement) is entered into effective as of May 14, 2015 (the Effective Date), by and between EXCO Resources, Inc., a Texas corporation (EXCO), and Richard A. Burnett (Executive). This Agreement amends, restates, and replaces that certain EXCO Resources, Inc. Retention Agreement by and between EXCO and Executive dated September 1, 2014 (the Prior Agreement) in its entirety.

EXCO Resources, Inc. – Exco Resources, Inc. Amended and Restated Retention Agreement (May 20th, 2015)

This Amended and Restated Retention Agreement (this Agreement) is entered into effective as of May 14, 2015 (the Effective Date), by and between EXCO Resources, Inc., a Texas corporation (EXCO), and Harold L. Hickey (Executive). This Agreement amends, restates, and replaces that certain EXCO Resources, Inc. Bonus and Retention Agreement by and between EXCO and Executive dated January 17, 2014 (the Prior Agreement) in its entirety.

EXCO Resources, Inc. – Exco Resources, Inc. Amended and Restated Retention Agreement (May 20th, 2015)

This Amended and Restated Retention Agreement (this Agreement) is entered into effective as of May 14, 2015 (the Effective Date), by and between EXCO Resources, Inc., a Texas corporation (EXCO), and William L. Boeing (Executive). This Agreement amends, restates, and replaces that certain EXCO Resources, Inc. Bonus and Retention Agreement by and between EXCO and Executive dated January 17, 2014 (the Prior Agreement) in its entirety.

Amended & Restated Severance Agreement (March 19th, 2015)

THIS AMENDED & RESTATED SEVERANCE AGREEMENT (this Agreement) is made as of , 20 , (the Effective Date) between Harte-Hanks, Inc., a Delaware corporation (the Company), and (the Executive).

December 15, 2014 (February 25th, 2015)

On behalf of HTG Molecular Diagnostics, Inc. (the Company), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (this Agreement). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Companys common stock, pursuant to which such common stock is priced for the initial public offering (the Effective Date). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated April 27, 2011(the Prior Agreement), as provided in Section 12 below.

December 15, 2014 (February 25th, 2015)

On behalf of HTG Molecular Diagnostics, Inc. (the Company), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (this Agreement). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Companys common stock, pursuant to which such common stock is priced for the initial public offering (the Effective Date). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated March 4, 2014(the Prior Agreement), as provided in Section 12 below.

December 15, 2014 (February 25th, 2015)

On behalf of HTG Molecular Diagnostics, Inc. (the Company), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (this Agreement). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Companys common stock, pursuant to which such common stock is priced for the initial public offering (the Effective Date). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated March 30, 2011 (the Prior Agreement), as provided in Section 12 below.

Town Sports International Holdings – Amended and Restated Executive Severance Agreement (February 25th, 2015)

Amended and Restated Executive Severance Agreement, dated as of February 25, 2015 (this Agreement), between Town Sports International Holdings, Inc. (Holdings and collectively with its subsidiaries and affiliates being referred to as the Company) and [Name of Executive] (the Executive).

December 15, 2014 (February 25th, 2015)

On behalf of HTG Molecular Diagnostics, Inc. (the Company), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (this Agreement). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Companys common stock, pursuant to which such common stock is priced for the initial public offering (the Effective Date). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated January 12, 2012 (the Prior Agreement), as provided in Section 12 below.

December 15, 2014 (February 25th, 2015)

On behalf of HTG Molecular Diagnostics, Inc. (the Company), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (this Agreement). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Companys common stock, pursuant to which such common stock is priced for the initial public offering (the Effective Date). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated January 7, 2008 (the Prior Agreement), as provided in Section 12 below.

Town Sports International Holdings – February 25, 2015 (February 25th, 2015)
Cell Therapeutics, Inc. – - Tosedostat Currently in Phase 2 Development for Patients With AML and MDS - - Acquisition Eliminates Potential $209 Million in Future Developmental and Sales Milestone Payments by CTI Under Prior Agreement With Chroma - (October 27th, 2014)

"Our portfolio strategy is to acquire novel best-in-class agents that, either as monotherapy or in combination with other therapies, can have a profound effect in the treatment of patients with blood related cancers," said James A. Bianco, M.D., President and CEO of CTI. "We are committed to building our blood-related cancer franchise. We feel there is strong interest in this oral, once-daily drug candidate, which we believe is attributable to the positive clinical results to date, and we are pleased to have exclusive worldwide rights to develop tosedostat for patients in areas where there remains an unmet medical need. Over the next year, CTI and its advisors intend to develop a registration path for tosedostat in the US and Europe. In the event of positive clinical data and productive regulatory discussions, we would intend to start a pivotal program commencing in 2016."

Cellceutix – Amendment to Menon- Cellceutix Agreement Without Changing the Total Amount of Royalties Payable Under the Terms of the Prior Agreement (September 2nd, 2014)

This Amendment, effective on signature of the last party to sign ("Effective Date"), between Dr. Krishna Menon, (hereinafter "Menon") and Cellceutix Corporation, a Nevada corporation located at 100 Cummings Center, Suite 151, Beverly MA 01915 USA (hereinafter "Cellceutix"), amends a prior agreement between these parties dated October 17, 2007 ("Prior Agreement" Attachment A hereto), by which Menon assigned to Cellceutix all right, title and interest to a Compound (as defined therein) and patents thereon in consideration for a percentage of Net Sales of the Compound, also known as Kevetrin.

Civitas Therapeutics, Inc. Third Amended and Restated Investors Rights Agreement (August 26th, 2014)

THIS THIRD AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT is made as of the 22nd day of August, 2014, by and among Civitas Therapeutics, Inc., a Delaware corporation (the Company), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an Investor.

Amendment (August 22nd, 2014)

THIS AMENDMENT TO THE AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT ("Amendment") is made and entered into on August 20, 2014, (the "Effective Date") by and between Wireless Ronin Technologies, Inc., a corporation duly organized and existing under the laws of the State of Minnesota, with a place of business at Baker Technology Plaza, 5929 Baker Road, Suite 475, Minnetonka, Minnesota 55345 (hereinafter referred to as the "Company"), and Scott W. Koller, a resident of the state of Minnesota (hereinafter referred to as "Executive"). This Amendment amends the Amended and Restated Executive Employment Agreement dated December 28, 2010, by and between the Company and Executive (the "Prior Agreement").

Cifc Corp. Amended and Restated Non-Disclosure, Non-Competition, Non-Hiring, Non-Solicitation and Severance Agreement (June 17th, 2014)

This AMENDED AND RESTATED NON-DISCLOSURE, NON-COMPETITION, NON-HIRING, NON-SOLICITATION AND SEVERANCE AGREEMENT (this Agreement) is made and entered into as of June 13, 2014 between CIFC Corp., (together with its Affiliates, as defined below, the Company) and Stephen Vaccaro (the Employee):

Ulthera Inc – Ulthera, Inc. Matthew E. Likens Amended and Restated Employment Agreement (May 13th, 2014)

This Amended and Restated Employment Agreement (this Agreement) is entered into effective as of May 12, 2014 (the Effective Date) by and between Ulthera, Inc., a Delaware corporation (the Company), and Matthew E. Likens (Executive). This Agreement amends and restates in its entirety that certain employment agreement by and between Executive and the Company effective as of July 31, 2006 (the Prior Agreement). For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows.

Amended and Restated Transition Agreement (May 13th, 2014)

This AMENDED AND RESTATED TRANSITION AGREEMENT (the "Agreement") is entered into effective May 8, 2014 by and between Peabody Energy Corporation, a Delaware corporation (the "Company"), and Gregory H. Boyce ("Executive"). This Agreement amends and restates the Transition Agreement between the Company and Executive, dated as of April 29, 2013 (the "Prior Agreement"). The Company and Executive hereby agree that upon full execution hereof, the Prior Agreement shall be of no further force or effect.

Ambrx Inc – Ambrx, Inc. Amended and Restated Registration Rights Agreement (May 2nd, 2014)

This Amended and Restated Registration Rights Agreement (this Agreement) is made and entered into as of March 17, 2009 (the Effective Date) by and among Ambrx, Inc., a Delaware corporation (the Company) and the persons and entities set forth on Schedule A attached hereto (the Investors).

Lands' End, Inc. – Prior Agreement; Term. (April 8th, 2014)

This Buying Agency Agreement (Agreement) is entered between LANDS END, INC., a Delaware corporation (LE) and SEARS HOLDINGS GLOBAL SOURCING, LTD., a Hong Kong corporation (SHGS). SHGS and LE each are sometimes referred to as a Party and together sometimes are referred to as the Parties.

Torvec Inc – Amended and Restated Investors' Rights Agreement (March 28th, 2014)

THIS AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT is made as of the 28 day of March, 2014, by and among Torvec, Inc., a New York corporation (the "Company"), B. Thomas Golisano, a resident of the State of Florida (the "Investor"), and Charles T. Graham and David Still (collectively, the "Additional Investors"). The "Investor" and the "Additional Investors" are referred to collectively as the "Purchasers."

Lands' End, Inc. – Prior Agreement; Term. (March 11th, 2014)

This Buying Agency Agreement (Agreement) is entered between LANDS END, INC., a Delaware corporation (LE) and SEARS HOLDINGS GLOBAL SOURCING, LTD., a Hong Kong corporation (SHGS). SHGS and LE each are sometimes referred to as a Party and together sometimes are referred to as the Parties.

Employment Agreement (February 27th, 2014)

THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Agreement), effective as of December 7, 2012 (the Effective Date), supercedes and replaces the Amended and Restated Employment Agreement dated February 8, 2008 (the Prior Agreement) by and between SCYNEXIS, Inc., a Delaware corporation (Employer or Company) and Chuck Osborne (Employee). Once this Agreement is in effect, the Prior Agreement shall have no further force or effect.

Celladon Corp – August 31, 2013 Ryan K. Takeya (January 28th, 2014)

On behalf of Celladon Corporation (the Company), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (the Agreement). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Companys common stock, pursuant to which such common stock is priced for the initial public offering (the Effective Date). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated January 30, 2012 (the Prior Agreement), as provided in Section 12 below.

Celladon Corp – August 31, 2013 (January 28th, 2014)

On behalf of Celladon Corporation (the Company), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (the Agreement). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Companys common stock, pursuant to which such common stock is priced for the initial public offering (the Effective Date). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated March 29, 2012 (the Prior Agreement), as provided in Section 12 below.

Celladon Corp – August 31, 2013 Rebecque Laba (January 28th, 2014)

On behalf of Celladon Corporation (the Company), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (the Agreement). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Companys common stock, pursuant to which such common stock is priced for the initial public offering (the Effective Date). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated September 24, 2007, as amended in April 2012 (the Prior Agreement), as provided in Section 12 below.

Celladon Corp – August 31, 2013 Jeffrey J. Rudy (January 28th, 2014)

On behalf of Celladon Corporation (the Company), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (the Agreement). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Companys common stock, pursuant to which such common stock is priced for the initial public offering (the Effective Date). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated May 3, 2006 (the Prior Agreement), as provided in Section 12 below.

Flexion therapeutics – August 28, 2013 Dear Art: (January 8th, 2014)

This letter agreement (the Agreement) sets forth the terms of your continued employment with Flexion Therapeutics, Inc. (the Company), in the full time position of Chief Business Officer, reporting to Michael Clayman, Chief Executive Officer. This Agreement will become effective upon your execution below. As of its effective date this Agreement will replace and supersede in its entirety the letter agreement between you and the Company dated May 10, 2012 (the Prior Agreement), except that the terms of your Proprietary Information, Inventions, Non-Solicitation, and Non-Competition Agreement executed on May 27, 2012 shall continue to apply.

Flexion therapeutics – Flexion Therapeutics, Inc. (January 8th, 2014)

This letter agreement (the Agreement) sets forth the terms of your continued employment as Chief Medical Officer (CMO) of Flexion Therapeutics, Inc. (the Company). This Agreement will become effective upon your acceptance by executing this Agreement and returning the executed Agreement to me. As of its effective date this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated November 15, 2007 (the Prior Agreement) except that the terms of your Proprietary Information and Inventions Agreement executed on January 7, 2010 shall continue to apply.

Flexion therapeutics – Flexion Therapeutics, Inc. (January 8th, 2014)

This letter agreement (the Agreement) sets forth the terms of your continued employment as Chief Executive Officer (CEO) and President with Flexion Therapeutics, Inc. (the Company). This Agreement will become effective upon your acceptance by executing this Agreement and returning the executed Agreement to me. As of its effective date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated November 8, 2007 (the Prior Agreement), except that the terms of your Proprietary Information and Inventions Agreement executed on March 10, 2009 shall continue to apply.

Amended and Restated Investors Rights Agreement (December 30th, 2013)

THIS AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT is made as of the 4th day of December, 2013, by and among Eleven Biotherapeutics, Inc., a Delaware corporation (the Company), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an Investor, and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.

Celladon Corp – August 31, 2013 (October 11th, 2013)

On behalf of Celladon Corporation (the Company), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (the Agreement). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Companys common stock, pursuant to which such common stock is priced for the initial public offering (the Effective Date). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated March 29, 2012 (the Prior Agreement), as provided in Section 12 below.